Phase 2 N=19 Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma
Adult Brain Tumor
Primary: Number of Participants With Objective Response — 3; 1; 5; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
Anaplastic Astrocytoma
Primary: Number of Participants With Objective Response — 2; 3; 6; 10 Participants
Phase 3 N=230 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
Brain and Central Nervous System Tumors
Primary: (Phase III) Overall Survival (OS) — 3.9; 3.8 years — p=0.36
N/A N=1 Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma
Astrocytoma, Grade III
Primary: Number of Participants Showing no Evidence of Disease Progression Six Months After Initiating Treatment With the Device. — 1 Participants
Phase 2 N=30 A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
Anaplastic Astrocytoma · Glioblastoma
Primary: Number of Participants With Progression Free Survival (PFS) at 6 Months Utilizing McDonald Criteria for Response, Progression and Relapse — 4; 2; 2 Participants
Phase 2 N=11 Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
Low Grade Astrocytomas
Primary: Number of Participants With Objective Response — 4; 1; 4; 0 Participants
Phase 2 N=74 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
Anaplastic Glioma of Brain · Glioblastoma Multiforme · Brain Cancer
Primary: 12 Month-progression-free Survival for Participants With Anaplastic Tumors — 44 percentage of participants
Phase 2 N=55 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Brain and Central Nervous System Tumors
Primary: Proportion of Participants With Objective Response Rate (ORR) — 5 Participants
Phase 2 N=40 Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme
Glioblastoma Multiforme of the Brain
Primary: Number of Participants With Objective Response — 1; 1; 5; 19 Participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme
Glioblastoma Multiforme of Brain
Primary: Number of Participants With Objective Response — 2; 1; 2; 27 Participants
Phase 2 N=20 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
Mixed Gliomas
Primary: Number of Participants With Objective Response — 3; 0; 4; 10 Participants
Phase 2 N=60 Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
CNS Cancer · CNS BRAIN
Primary: Progession Free Survival — 85.7 % of participants without progression
Phase 1 N=9 Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
Glioblastoma Multiforme/Anaplastic Astrocytoma
Primary: Maximum Tolerated Dose(MTD)of Temozolomide(TMZ) — 75 mg/m^2
Phase 2 N=31 Low Dose Radiation Therapy for Glioblastoma Multiforme
High Grade Glioma
Primary: Response Rate
Phase 2 N=45 Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: PFS-6 — 1; 8 Participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Brain Stem Glioma
Brain Stem Gliomas
Primary: Number of Participants With Objective Response — 5; 4; 8; 14 Participants
Phase 2 N=20 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Anaplastic Astrocytomas · Anaplastic Oligodendrogliomas · Glioblastomas (GBM)
Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants
Phase 2 N=11 Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Glioblastoma Multiforme · Anaplastic Astrocytoma
Primary: Safety of Twice a Day Oral 150 mg Erlotinib Dosing — 9 participants
Phase 2 N=58 VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Progression-free Survival (PFS) at 6 Months — 25; 7.7 percentage of participants
Phase 2 N=41 Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
Glioblastoma Multiforme · Gliosarcoma
Primary: Response Rate — 22 percentage of participants
Phase 2 N=41 Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas
Glioblastoma · Gliosarcoma
Primary: Response Rate — 24.4 percentage of patients
Phase 1 N=71 Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
Astrocytoma, Grade III · Glioblastoma
Primary: Maximum Tolerated Dose (MTD) — 150; 150 mg
Phase 2 N=120 Temozolomide in Treating Patients With Low-Grade Glioma
CNS Tumor, Adult
Primary: Response Rate (Complete and Partial Response) — 7 Participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Brain Tumors
Refractory Brain Tumors
Primary: Number of Participants With Objective Response — 4; 5; 12; 10 Participants
Phase 2 N=25 TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Astrocytoma
Primary: Progression Free Survival at 6 Months (PFS6) — 47 percentage of participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Malignant Brain Tumors
Primary: Number of Participants With Objective Response — 2; 2; 4; 19 Participants
Phase 2 N=60 Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Recurrent Central Nervous System Neoplasm
Primary: 6 Month Progression-free Survival — 10; 50 percentage of patients
Phase 2 N=12 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
Visual Pathway Glioma
Primary: Number of Participants With Objective Response — 2; 2; 3; 1 Participants
Phase 2 N=80 Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
Malignant Glioma · Glioblastoma · Gliosarcoma
Primary: 6-month Progression-free Survival — 88.8 percentage of participants
Phase 2 N=182 A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma
Glioblastoma Multiforme
Primary: Percentage of Participants Achieving Progression-Free Survival (PFS) Without Disease Progression or Death at 6 Months — 79.31; 42.59 percentage of participants — p=<0.0001